Enanta Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jay R. Luly
- Full Time Employees
- 131
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Arsenal Street Watertown MA United States of America 02472
- IPO Date
- Mar 21, 2013
- CIK
- 0001177648
- Website
- enanta.com
- Similar Companies
- Business
- Enanta Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, specializing in the discovery and advancement of small molecule therapeutics for challenging viral infections and various immunological conditions. The firm’s active research and development pipeline includes programs aimed at respiratory syncytial virus (RSV), hepatitis B virus (HBV), and emerging immunology targets such as KIT and STAT6 inhibition for inflammatory diseases. Notably, Enanta continues to benefit from its collaboration with AbbVie, having contributed glecaprevir to the highly successful MAVYRET® regimen for chronic hepatitis C virus infection. Established in 1995, Enanta Pharmaceuticals, Inc. has its headquarters in Watertown, Massachusetts.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference